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Abstract
Background:  The metabolic inhibitor rotenone inhibits hepatocellular proliferation and the
incidence of liver cancer resulting from exposure to the PPARα agonist Wy-14,643, via unknown
mechanisms. Since the absence of thyroid hormones diminishes hepatomegaly, an early biomarker
for the hepatocarcinogenicity induced by PPARα agonists, this study was undertaken to investigate
whether rotenone might interference with the ability of Wy-14,643 to alter the animal thyroid
status.
Methods: Male B6C3F1 mice were given Wy-14,643 (100 ppm), rotenone (600 ppm) or a mixture
of both, in the feed for 7 days. Bromodeoxyuridine (BrDU), marker of cell replication, was
delivered through subcutaneously implanted osmotic mini-pumps. At the end of the experiment,
sera were collected and corticosterone and thyroid hormone levels were measured by solid-phase
radioimmunoassay kits. In addition, liver tissue samples were stained immunohistochemically for
BrDU to determine percentages of labeled cells. Further, cell surface area was determined from
images generated by a Zeiss Axioplan microscope equipped with a plan Neofluar ×40 0.75 na
objective. Tracings of individual hepatocyte perimeters were then analyzed and cell-surface areas
were calculated using MicroMeasure FL-4000.
Results: Wy-14,643 caused a significant increase in liver weights, hepatocyte BrDU labeling index
(LI), and hepatocyte surface area. In animals which received both Wy-14,643 and rotenone
simultaneously, all of these effects were significantly less pronounced compared with mice that
received Wy-14,643 alone. Rotenone alone decreased liver weights, LI and surface area. The Free
Thyroid Index (FTI), which provides an accurate reflection of the animal's thyroid status, was 5.0 ±
0.3 in control mice. In animals exposed to rotenone, these values decreased to 2.0 ± 0.9, but in
animals which received Wy-14,643, levels increased significantly to 7.7 ± 0.9. FTI values decreased
to 3.4 ± 0.8 in mice receiving both rotenone and Wy-14,643.
Conclusion: A strong correlation was observed between the animal thyroid status and both,
hepatocyte proliferation  (r2 = 0.62), and hepatocyte surface area (r2 = 0.83). These results support
the hypothesis that the thyroid status of the animal plays a role in PPARα-induced hepatocellular
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proliferation and liver cell enlargement. Both these events are known to contribute to the
expression of liver cancer in response to the activation of PPARα.
Background
Although hepatocellular neoplasms occurred in wild-
type, but not in PPARα-null mice upon exposure to
PPARα agonists [1,2], molecular mechanisms involved in
this effect remained unknown. However, important fac-
tors involved in this hepatocarcinogenic effect are thought
to include: (i) enhanced hepatic oxidative stress due to
elevated peroxisomal and nonperoxisomal oxidative
metabolism, (ii) inhibition of apoptosis in livers of
exposed animals, and/or (iii) increased hepatocellular
proliferation [3,4].
Thyroid hormones have been shown by our laboratory [5]
as well as by others [6] to alter hepatic responses to PPARα
agonists, including hepatomegaly, an early biomarker for
the hepatocarcinogenicity induced by these compounds
[7,8]. Hepatomegaly was blunted in thyroidectomized
animals treated with PPAR agonists, compared with intact
animals [5,6]; however, the contribution of hyperplasia
and hypertrophy to this effect is not known. Furthermore,
agonists of PPARα impart a thyromimetic effect in
exposed animals [9]. This effect is significantly more pro-
nounced in intact animals compared with thyroidect-
omized counterparts [5]. These findings suggest that
thyroid hormones may play a role in the effects attributed
to the activation of PPARα, including hepatocellular
cancer.
Previously, our laboratory [10], as well as others [11] have
reported that the pesticide rotenone inhibited hepatocel-
lular proliferation induced by the PPARα agonist Wy-
14,643, and also reduced the incidence of liver cancer
resulting from exposure to Wy-14,643 [11]. Conse-
quently, this study was undertaken to investigate whether
rotenone blocks the hepatic effects of the PPARα agonist
Wy-14,643 by potentially interfering with its ability to
modulate the animal thyroid status. The results demon-
strate that rotenone and Wy-14,643 produced opposing
effects on thyroid hormone levels. They also show a
strong correlation between the animal thyroid status and
both hepatocyte proliferation (r2 = 0.62), and hepatocyte
surface area (r2 = 0.83). In conclusion, the results suggest
that thyroid hormones play a major role in the events
known to contribute to the expression of liver cancer in
response to the activation of PPARα. These events include
hepatocellular proliferation and hepatocyte enlargement.
Methods
Animal treatment
Male B6C3FI mice (Charles River, Potage, Michigan)
weighing 25 ± 2 gram were maintained on a daily cycle of
alternating 12 h periods of light and darkness, with room
temperature set at 22 ± 2°C and on a standard Purina diet
for seven days prior to experiment. Mice were then fed
Wy-14,643 (100 ppm), rotenone (600 ppm) or a mixture
of both blended in the feed for 7 days. Water was supplied
ad labitum. Our experimental protocol was approved by
the Institutional Animal Care and use Committee, and
experiments were performed in accordance with estab-
lished guidelines for care and use of animals.
Measurement of cell proliferation
Osmotic minipumps (Alza Cooperation, palo Alto, CA,
model 2002) were implanted subcutaneously into the
backs of the mice to deliver bromodeoxyuridine (30 mg/
ml) which is incorporated into DNA of replicating cells.
Seven days later, animals were euthanized by CO2 inhala-
tion. Following determination of liver weights, a mid-lobe
radial section of the right anterior lobe was fixed in neu-
tral buffered formalin for 24 h. A cross section of small
intestine was also fixed as a positive control for the proper
operation of the mini-pump and the staining technique
because these cells are constantly in S phase. Tissues were
embedded in paraffin and serial sections were mounted
onto poly-l-lysine-coated slides. After deparafination and
rehydration, slides were stained immunohistochemically
for BrDU incorporation [12]. Random areas of the slides
were chosen for counting stained and unstained hepato-
cyte nuclei (>1000 hepatocytes/animal).
Determination of cell surface area
Mice were fed control diet or a diet containing rotenone
(600 ppm), Wy-14,643 (100 ppm) or a mixture of both
for 7 days prior to these experiments. Using a Zeiss Axio-
plan microscope equipped with a plan Neofluar ×40 0.75
na objective (Carl Zeiss, Inc., Thornwood, NJ), individual
hepatocyte perimeters were traced by a mouse-driven
pointer. Generated images were analyzed and cell-surface
areas were calculated using a commercial software (Micro-
Measure FL-4000, Georgia Instruments, Inc., Rosswell,
GA), as described previously [13,14].
Serum corticosterone and thyroid hormone levels
Hormones were quantified in sera. Corticosterone levels
were measured using a solid-phase radioimmunoassay kit
(Diagnostic Products Corporation, Los Angeles, CA). In
this assay, 125I-labeled rat corticosterone was allowed toJournal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/9
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compete with serum corticosterone for antibody sites in
the sample. Since corticosterone levels follow diurnal var-
iations, assays were done at the same time periods for the
different treatment groups. Both, T3 and T4, as well as T3
value uptake were detected using a solid-phase chemilu-
minescent enzyme immunoassay kits (Diagnostic Prod-
ucts Corporation, Los Angeles, CA). The Free Thyroxine
Index of Clark and Horn, which provides a more accurate
picture of thyroid status [15], was calculated according to
the manufacturer's instructions [(T3% Uptake/100) × T4
µg/dl].
Statistical Analysis
Data were analyzed by ANOVA (Stat Work™), and statisti-
cal significance was defined as p < 0.05. All data reported
are means ± SEM of 4–7 mice per group.
Results
Liver/body weight ratios, hepatocyte proliferation and 
surface area in treated mice
Liver/body weight ratios in control mice were 5.3 ± 1.02%
(Fig. 1A). These ratios did not change in animals treated
for seven days with rotenone (Fig. 1A). However, as
expected in mice treated with Wy-14,643, ratios increased
significantly to 8.8 ± 0.17% (Fig 1A). In animals treated
with a mixture of Wy-14,643 and rotenone, the ratio was
increased to only 7.5 ± 0.9%, which is significantly lower
than those obtained with Wy-14,643 alone (Fig. 1A).
The BrDU labeling index in control mice was 6.7 ± 1.4%
(Fig. 1B). Treatment with Wy-14,643 increased labeling
indices significantly to 27.2 ± 4.30% (Fig. 1B). However,
animals treated with a mixture of rotenone and Wy-
14,643 had a BrDU labeling index which was significantly
lower compared to those which received Wy-14,643
alone, nonetheless they were higher than control values
(Fig. 1B). Rotenone alone decreased the BrDU labeling
index by 50% (Fig. 1B).
Hepatocyte surface area in control mice was 318 ± 18 µm2
(Fig. 1C). Seven days following treatment with Wy-
14,643, cell size increased significantly to 765 ± 36 µtm2,
while feeding mice a diet containing a mixture of Wy-
14,643 and rotenone resulted in a cell size of 387 ± 17
µm2 which is approximately that of the control mice and
significantly less than values observed in mice treated
with Wy-14, 643 alone (Fig. 1C). Animals treated with
rotenone alone showed a 24% reduction in cell surface
area, compared to control animals (Fig. 1C),
Perturbation of serum hormone levels by rotenone
Feeding mice diets containing rotenone, Wy-14,643, or a
combination of both compounds did not alter serum T3
levels. These levels ranged from 42.4 ± 1.7 U% to 49.5 ±
1.2 U% among all tested groups (Fig 2A). However, when
given separately, rotenone and Wy-14,643 produced
opposing effects on serum T4 levels. While rotenone
decreased these levels significantly by 60% (from 10.5 ±
0.65 µg/dl to 4.2 ± 0.5 µg/dl), Wy-14,643 almost doubled
serum T4 to 18.0 ± 1.6 µg/dl (Fig 2B). Mice which simul-
taneously received rotenone and Wy-14,643 showed
serum T4 levels of 6.1 ± 1.2 mg/dl (Fig 2B). The Free Thy-
roid Index (FTI), which accurately reflects the animal thy-
roid status [15], closely followed changes in serum T4
levels. FTI was 5.0 ± 0.3 in control mice (Fig 2C). These
values decreased following exposure to rotenone to only
2.0 ± 0.9, but increased significantly to 7.7 ± 0.9 in ani-
mals which received Wy-14,643 alone (Fig 2C). Similar to
T4, FTI values were lower in mice receiving rotenone and
Wy-14,643 simultaneously (3.4 ± 0.8), compared with
control mice (Fig 2C).
Mice which received drug-free diet had serum corticoster-
one levels of 159 ± 33 ng/ml (Fig 3). These levels were
increased by 3 fold in mice fed rotenone-containing diet
(Fig 3). However, Wy-14,643 failed to alter serum corti-
costerone levels significantly, where levels remained at
181 ± 3 ng/ml (Fig 3). The diet containing both rotenone
and Wy-14,643 resulted in animal serum corticosterone
levels which were 27% lower than those in mice exposed
to rotenone alone, yet 2-fold higher than detected in sera
of control mice (Fig 3).
Correlation between serum hormone levels and hepatic 
changes
There was a strong correlation between the animal thyroid
status and both, hepatocyte proliferation (r2 = 0.62, Fig
4A), and hepatocyte surface area (r2 = 0.83, Fig 4B). While
diet containing Wy-14,643 significantly elevated the Free
Thyroid Index (Fig 2C), and increased hepatocyte BrU
labeling indices (Fig 1B), and hepatocyte surface area (Fig
1C), co-administration of rotenone with Wy-14,643
reduced all parameters toward control values (Figs 1&4).
Rotenone alone decreased all parameters to levels below
control values (Figs 1&4).
Conversely, there was a poor correlation (r2  = 0.26)
between serum corticosterone levels and hepatocyte BrU
labeling indices (Fig 4C). For example, while diet contain-
ing Wy-14,643 did not significantly alter serum corticos-
terone levels (Fig 3), labeling indices in animals receiving
this diet were 4 folds higher compared with control mice
(Fig. 2B).
Similarly, serum corticosterone levels did not correlate
well (r2 = 0.35) with changes in hepatocyte surface area
(Fig 4D).Journal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/9
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Liver/body weight ratios, hepatocellualr proliferation and surface area Figure 1
Liver/body weight ratios, hepatocellualr proliferation and surface area. Mice were fed control diet or a diet contain-
ing Wy-14,643 (100 ppm), rotenone (600 ppm), or a mixture of both for seven days. Animal body and liver weights were 
recorded, and ratios were calculated (A). Bromodeoxyuridine incorporation into hepatocyte DNA (B), and hepatocyte sur-
face areas (C) were determined as detailed under "Materials and Methods". Data are means ± SEM from 4–6 mice per group. * 
P < 0.05 compared to control values. **p < 0.05 compared to rotenone values, and ***p < 0.05 compared to Wy-14,643 
values.
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Perturbations of serum thyroid levels by rotenone and Wy-14,643 Figure 2
Perturbations of serum thyroid levels by rotenone and Wy-14,643. Animals were treated, and sera were collected, 
and analyzed, as detailed under "Materials and Methods", for T3 (A), and T4 (B). Free Thyroxine Index (C) was calculated 
[(T3% Uptake/100) × T4 µg/dl]. Data are means ± SEM from 4–6 mice per group. * P < 0.05 compared to control values. **p < 
0.05 compared to rotenone values, and ***p < 0.05 compared to Wy-14,643 values.
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Discussion
The non-genotoxic hepatocarcinogens, PPARα agonists,
elicit marked liver enlargement; encompassing an
increase in both, cell number (hyperplasia) as well as cell
size (hypertrophy). Hyperplasia results from the stimula-
tion of DNA synthesis and subsequent cell division [16].
A probable causal link between the hyperplasia and the
subsequent development of liver tumors in rodents has
been suggested [17-19]. The potential role of hypertrophy
in the hepatocarcinogenic effect of PPAR agonists is not
clear, and differential mechanisms controlling these two
phenomena are not understood.
Rotenone inhibits hepatocellular proliferation and
reduces the incidence of liver cancer resulting from expo-
sure to the PPARα agonist Wy-14,643 [10,11]. Con-
versely, thyroid hormones are known to mediate hepatic
responses to PPARα agonists [5,6]. Hepatomegaly, which
is considered an early biomarker for the hepatocarcino-
genicity induced by these nongenotoxic hepatocarcino-
gens [7,8], is blunted in thyroidectomized animals [5,6],
and PPAR agonists impart a thyromimetic-like effect in
exposed animals [9]. Accordingly, we sought to investi-
gate whether rotenone alters the animal thyroid status, in
a manner that may explain its antagonistic effects of hepa-
tocellular responses to the PPARα agonist Wy-14,543
[10,11].
In this study, the hepatocarcinogen Wy-14,643 and the
antihepatocarcingen rotenone produced opposing effects
on hepatocellular proliferation (Fig 1B), hepatocyte sur-
face area (Fig 1C), and Free Thyroid Index (FTI; Fig 2C).
While rotenone decreased all three parameters signifi-
cantly, Wy-14,643 caused remarkable increases in these
parameters. These values were lower in mice receiving
rotenone and Wy-14,643 simultaneously, compared with
mice that received Wy-14,643 alone. There was a strong
positive correlation between FTI and both BrDU labeling
(r2 = 0.62; Fig 4A), as well as with hepatocyte surface area
(r2 = 0.83; Fig 4B).
Increase in serum corticosterone levels by rotenone Figure 3
Increase in serum corticosterone levels by rotenone. Corticosterone was quantified in sera from various animal groups 
as described under "Materials and Methods". Data are means ± SEM from 4–6 mice per group. * P < 0.05 compared to control 
values. **p < 0.05 compared to rotenone values, and ***p < 0.05 compared to Wy-14,643 values.
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In contrast to thyroid hormone levels, and in agreement
with a recent study from our laboratories [20], rotenone
increased serum corticosterone levels (Fig 3). Wy-14,643,
on the other hand, failed to alter these levels (Fig 3). Based
on these findings, we previously suggested that increasing
serum glucocorticoid levels by rotenone may, at least in
part, explain the anticarcinogenic effect of this compound
[20]. Results of the current study support the hypothesis
that decreasing serum thyroid hormone levels may play a
more prominent role, compared with that of glucocorti-
coids, in the mechanism of antihepatocarcingenicity
attributed to rotenone. Animals receiving diet containing
both rotenone and Wy-14,643 showed serum corticoster-
one levels which were 27% lower than those caused by
rotenone alone, yet 2-fold higher than detected in sera of
control mice (Fig 3). Yet, poor correlation was found
between serum corticosterone levels and either BrDu (r2 =
0.26; Fig 4C), or hepatocyte surface areas (r2 = 0.35; Fig
4D). In previous studies [21,22], it was shown that while
corticosterone mediated hepatomegaly and liver hyper-
trophy due to the organochlorine mirex, thyroid hor-
mones exclusively mediated liver hyperplasia due to this
compound. The current studies, however, show that
increasing serum corticosterone levels by rotenone was
accompanied by a decrease in hepatomegaly as well as
diminished hypertrophy in response to Wy-14,643 (Fig
Correlation between serum hormone levels and hepatocellular changes Figure 4
Correlation between serum hormone levels and hepatocellular changes. Relationship between serum thyroid hor-
mone and corticosterone levels and either hepatocye BrDU labeling (A,C), or hepatocyte surface area (B,D) were evaluated. 
Regression coefficient analyses were performed using the Prism Software (GraphPad Software, Inc., San Diego, CA).
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1). Furthermore, exposure to rotenone alone, which
increased serum glucocorticoid levels remarkably (Fig 3),
diminished hepatic hypertrophy (Fig 1C). It is possible
that the simultaneous effect of rotenone on thyroid hor-
mone levels, in addition to corticosterone, is responsible
for this observation.
In conclusion, thyroid status appears to regulate PPARα-
controlled increases in hepatocellular proliferation and
liver cell enlargement; events known to contribute to the
expression of liver cancer. Further, diminishing Wy-
14,643's induction of serum thyroid hormone levels may
represent an important aspect of the mechanism by which
rotenone reduces the formation of hepatocellular cancer
in response to Wy-14,643.
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